[go: up one dir, main page]

ATE308319T1 - Dosierungsform mit verlängerter wirkstoffabgabe - Google Patents

Dosierungsform mit verlängerter wirkstoffabgabe

Info

Publication number
ATE308319T1
ATE308319T1 AT99908498T AT99908498T ATE308319T1 AT E308319 T1 ATE308319 T1 AT E308319T1 AT 99908498 T AT99908498 T AT 99908498T AT 99908498 T AT99908498 T AT 99908498T AT E308319 T1 ATE308319 T1 AT E308319T1
Authority
AT
Austria
Prior art keywords
dosage form
extended release
extended
release
dosage
Prior art date
Application number
AT99908498T
Other languages
English (en)
Inventor
David E Edgren
Shu Li
Gurdish K Bhatti
Patrick S L Wong
Robert R Skluzacek
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Application granted granted Critical
Publication of ATE308319T1 publication Critical patent/ATE308319T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Laminated Bodies (AREA)
AT99908498T 1998-03-06 1999-02-26 Dosierungsform mit verlängerter wirkstoffabgabe ATE308319T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7713398P 1998-03-06 1998-03-06
PCT/US1999/004192 WO1999044591A1 (en) 1998-03-06 1999-02-26 Extended release dosage form

Publications (1)

Publication Number Publication Date
ATE308319T1 true ATE308319T1 (de) 2005-11-15

Family

ID=22136264

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05075190T ATE486589T1 (de) 1998-03-06 1999-02-26 Osmotische dosierungsform mit verlängerter wirkstoffabgabe
AT99908498T ATE308319T1 (de) 1998-03-06 1999-02-26 Dosierungsform mit verlängerter wirkstoffabgabe

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT05075190T ATE486589T1 (de) 1998-03-06 1999-02-26 Osmotische dosierungsform mit verlängerter wirkstoffabgabe

Country Status (13)

Country Link
US (1) US6245357B1 (de)
EP (3) EP1059916B1 (de)
JP (1) JP5143324B2 (de)
AR (1) AR015730A1 (de)
AT (2) ATE486589T1 (de)
AU (1) AU2791599A (de)
CY (1) CY1111153T1 (de)
DE (2) DE69928085T2 (de)
DK (1) DK1600154T3 (de)
ES (2) ES2248983T3 (de)
HK (1) HK1033649A1 (de)
PT (1) PT1600154E (de)
WO (1) WO1999044591A1 (de)

Families Citing this family (213)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US8524277B2 (en) * 1998-03-06 2013-09-03 Alza Corporation Extended release dosage form
CA2327685C (en) 1998-04-03 2008-11-18 Bm Research A/S Controlled release composition
US20050048120A1 (en) * 1998-11-04 2005-03-03 Edgren David Emil Dosage form comprising self-destructive membrane
ES2374717T3 (es) 1999-10-29 2012-02-21 Euro-Celtique S.A. Formulaciones de hidrocodona de liberación controlada.
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
EP1233761B1 (de) * 1999-11-22 2007-03-28 ALZA Corporation Osmotische darreichungsform mit zwei mantelschichten
KR100968128B1 (ko) * 2000-10-30 2010-07-06 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20110104214A1 (en) * 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
DE60227802D1 (de) * 2001-06-05 2008-09-04 Elan Pharma Int Ltd Mahlvorrichtung und verfahren zu deren betrieb
AU2002316582B2 (en) * 2001-07-06 2007-03-15 Endo Pharmaceuticals, Inc. Oral administration of 6-hydroxy-oxymorphone for use as an analgesic
US8329216B2 (en) * 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
WO2003004033A1 (en) * 2001-07-06 2003-01-16 Penwest Pharmaceuticals Company Sustained release formulations of oxymorphone
US6663896B1 (en) * 2001-08-01 2003-12-16 Alvin S. Blum Delayed release aspirin for vascular obstruction prophylaxis
WO2003015531A2 (en) * 2001-08-06 2003-02-27 Thomas Gruber Pharmaceutical formulation containing dye
US20150031718A1 (en) * 2001-08-06 2015-01-29 Purdue Pharma L.P. Pharmaceutical Formulation Containing Opioid Agonist, Opioid Antagonist and Gelling Agent
US20030068375A1 (en) * 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US6703045B2 (en) 2001-08-21 2004-03-09 Council Of Scientific & Industrial Research Composition and method for maintaining blood glucose level
ATE381924T1 (de) * 2001-09-21 2008-01-15 Egalet As Feste dispersionen mit kontrollierter freisetzung von carvedilol
US20040234602A1 (en) * 2001-09-21 2004-11-25 Gina Fischer Polymer release system
WO2003024430A1 (en) * 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
CA2459976A1 (en) * 2001-09-26 2003-04-03 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
US6821532B2 (en) * 2001-11-16 2004-11-23 Unitel Technologies, Inc. Methods and compositions for the treatment of benign prostatic hypertrophy
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US20050025791A1 (en) * 2002-06-21 2005-02-03 Julius Remenar Pharmaceutical compositions with improved dissolution
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7780987B2 (en) * 2002-02-21 2010-08-24 Biovail Laboratories International Srl Controlled release dosage forms
AU2003208761A1 (en) * 2002-02-21 2003-09-09 Amarin Development Ab A method for releasing nanosized particles of an active substance from a diffusion-controlled pharmaceutical composition for oral use
CA2477923C (en) 2002-03-01 2021-02-23 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
WO2003082207A2 (en) * 2002-03-29 2003-10-09 Alza Corporation Volume efficient controlled release dosage form
RU2004134594A (ru) * 2002-04-29 2005-06-27 Алза Корпорейшн (Us) Способы и лекарственные формы для контролируемой доставки оксикодона
US7776314B2 (en) * 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
NZ537492A (en) * 2002-06-28 2007-10-26 Alza Corp Oral dosage form comprising a liquid active agent formulation and controlling release thereof by an expandable osmotic composition
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
EP1539270A1 (de) * 2002-09-18 2005-06-15 Medtronic Vascular, Inc. Steuerbare, arznemittelfreisetzende gradientbeschichtungen für medizinische vorrichtungen
US20050020613A1 (en) * 2002-09-20 2005-01-27 Alpharma, Inc. Sustained release opioid formulations and method of use
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
AU2003287301A1 (en) * 2002-10-31 2004-06-07 Alza Corporation Dosage form providing ascending release of liquid formulation
CN1728982A (zh) * 2002-10-31 2006-02-01 阿尔扎公司 可增加疏水性药物生物利用度的药物制剂
WO2004041252A1 (en) 2002-11-08 2004-05-21 Egalet A/S Controlled release carvedilol compositions
AU2003291103A1 (en) * 2002-11-15 2004-06-15 Branded Products For The Future Pharmaceutical composition
CA2508722A1 (en) * 2002-12-11 2004-06-24 Pfizer Products Inc. Controlled-release of an active substance into a high fat environment
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
EP2339328A3 (de) 2002-12-30 2011-07-13 Transform Pharmaceuticals, Inc. Pharmazeutische kokristallisierte Celecoxib-Zusammensetzungen
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
EP1608339B8 (de) 2003-02-28 2012-04-25 McNeill-PPC, Inc. Pharmazeutische mischkristalle von celecoxib-nicotinamid
DE602004031096D1 (de) 2003-03-26 2011-03-03 Egalet As Morphin-system mit kontrollierter freisetzung
US8298581B2 (en) 2003-03-26 2012-10-30 Egalet A/S Matrix compositions for controlled delivery of drug substances
EP1613389B8 (de) * 2003-03-31 2008-05-07 Intarcia Therapeutics, Inc. Osmotische pumpe mit mitteln zum ableiten des innendrucks
US20040214893A1 (en) * 2003-04-11 2004-10-28 Matthew Peterson Gabapentin compositions
EP1626950A4 (de) 2003-05-23 2007-05-23 Transform Pharmaceuticals Inc Sertralinzusammensetzungen
WO2004108092A2 (en) * 2003-06-05 2004-12-16 P3 Laboratories, Inc. Tannate compositions and methods of use
WO2004110511A1 (en) * 2003-06-19 2004-12-23 Coloplast A/S A wound care device
US20050079220A1 (en) * 2003-07-31 2005-04-14 Betty Yu Osmotic engine & dosage form for controlled release of a liquid active agent formulation
DE102004032051A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US20070048228A1 (en) * 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) * 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US8075872B2 (en) * 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
EP1667653A1 (de) * 2003-09-26 2006-06-14 Alza Corporation Dosierform für die kontrollierte freisetzung einer wirkstoffformulierung
US20080031901A1 (en) * 2004-09-24 2008-02-07 Abbott Laboratories Sustained release monoeximic formulations of opioid and nonopioid analgesics
CN1897924B (zh) 2003-09-26 2011-09-21 阿尔扎公司 能提供高载药量的药物包衣和提供它的方法
WO2005030182A1 (en) * 2003-09-26 2005-04-07 Alza Corporation Controlled release formulations exhibiting an ascending rate of release
ATE363269T1 (de) * 2003-09-26 2007-06-15 Alza Corp Verbesserte dosierform mit kontrollierter freisetzung mit stehantrieb
AU2004275826A1 (en) * 2003-09-26 2005-04-07 Alza Corporation OROS push-stick for controlled delivery of active agents
WO2005030181A1 (en) * 2003-09-26 2005-04-07 Alza Corporation Controlled release formulations of opioid and nonopioid analgesics
BRPI0414941A (pt) * 2003-09-30 2006-11-07 Alza Corp dispositivo de distribuição de agente ativo acionado osmoticamente proporcionando um perfil de liberação ascendente
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
US20050113410A1 (en) * 2003-11-03 2005-05-26 Mark Tawa Pharmaceutical salts of zafirlukast
US7829552B2 (en) 2003-11-19 2010-11-09 Metabasis Therapeutics, Inc. Phosphorus-containing thyromimetics
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US20060004037A1 (en) * 2004-03-25 2006-01-05 Transform Pharmaceuticals, Inc. Novel tricyclic compounds and related methods of treatment
DK1765292T3 (en) 2004-06-12 2018-01-02 Collegium Pharmaceutical Inc ABUSE PREVENTIONAL PHARMACEUTICAL FORMULATIONS
JP5017103B2 (ja) * 2004-06-17 2012-09-05 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 薬剤共結晶組成物および関連した使用方法
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
WO2006002884A1 (de) * 2004-07-01 2006-01-12 Grünenthal GmbH Gegen missbrauch gesicherte, orale darreichtungsform
US20070043100A1 (en) 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
US8541026B2 (en) * 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
US8779175B2 (en) * 2004-10-25 2014-07-15 Synthonics, Inc. Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients
US20060160783A1 (en) * 2004-12-30 2006-07-20 Transform Pharmaceuticals, Inc. Novel omeprazole forms and related methods
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US8052996B2 (en) 2005-02-03 2011-11-08 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
DE102005005449A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
NZ563846A (en) * 2005-06-03 2010-03-26 Egalet As A drug delivery system for delivering active substances dispersed in a dispersion medium
CA2659215C (en) * 2005-07-27 2018-07-10 Dov Pharmaceutical, Inc. Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
BRPI0615860B8 (pt) * 2005-09-09 2021-05-25 Labopharm Barbados Ltd composição farmacêutica de liberação prolongada monolítica sólida
US20090022798A1 (en) * 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
US20100172989A1 (en) * 2006-01-21 2010-07-08 Abbott Laboratories Abuse resistant melt extruded formulation having reduced alcohol interaction
US20090317355A1 (en) * 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
FR2898056B1 (fr) * 2006-03-01 2012-01-20 Ethypharm Sa Comprimes resistant a l'ecrasement destines a eviter le detournement illicite
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
US20090306119A1 (en) * 2006-03-15 2009-12-10 Michael Keane Non-Codeine Opioid Analgesic Process And Formulations
US20080045725A1 (en) * 2006-04-28 2008-02-21 Murry Jerry A Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8765178B2 (en) 2006-07-19 2014-07-01 Watson Laboratories, Inc. Controlled release formulations and associated methods
PT2359808E (pt) 2006-08-09 2013-08-28 Intarcia Therapeutics Inc Sistemas de entrega osmótica e montagens de pistão
US9114133B2 (en) 2006-08-25 2015-08-25 U.S. Dept. Of Veterans Affairs Method of improving diastolic dysfunction
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US8138377B2 (en) * 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
US20080269348A1 (en) * 2006-11-07 2008-10-30 Phil Skolnick Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use
AU2008207200B2 (en) * 2007-01-16 2011-02-17 Egalet Ltd Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
KR20200123866A (ko) 2007-02-09 2020-10-30 메타베이시스 테라퓨틱스, 인크. 글루카곤 수용체의 길항제
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
PL2157967T3 (pl) 2007-04-23 2013-06-28 Intarcia Therapeutics Inc Formulacje zawiesinowe peptydów insulinotropowych i ich zastosowania
AU2008258596B2 (en) 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
US20090069374A1 (en) * 2007-06-06 2009-03-12 Phil Skolnick Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes, Methods For Their Preparation And Their Use As Medicaments
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
US20090124650A1 (en) * 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
CN101821276B (zh) 2007-08-13 2016-08-31 症变治疗公司 新颖的葡糖激酶活化剂
US8895066B2 (en) * 2007-10-16 2014-11-25 Paladin Labs Inc. Bilayer composition for the sustained release of acetaminophen and tramadol
US12011423B2 (en) 2007-11-06 2024-06-18 Foraviset Ltd. S-alkylisothiouronium derivatives for treating uterine hypercontractility disorders
BRPI0821732A2 (pt) 2007-12-17 2015-06-16 Labopharm Inc Formulações de liberação controlada , forma de dosagem sólida, e, uso da formulação de liberação controlada
JP5774853B2 (ja) 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US20090232896A1 (en) * 2008-03-11 2009-09-17 Mallinckrodt Inc. Use of Magnesium Stearate Dihydrate for Lubrication of Solid Pharmaceutical Compositions
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
EP2262484B1 (de) * 2008-03-11 2013-01-23 Depomed, Inc. Gastroretentive darreichungsformen mit verzögerter freisetzung mit komibinationen aus einem nichtopioiden analgetikum und einem opioiden analgetikum
EP2273983B1 (de) 2008-05-09 2016-07-20 Grünenthal GmbH Verfahren für die zubereitung eines pulverförmigen zwischenprodukts und einer endgültigen festen darreichungsform anhand eines sprüherstarrungsschrittes
ES2527670T3 (es) 2008-08-13 2015-01-28 Metabasis Therapeutics, Inc. Antagonistas de glucagón
WO2010069050A1 (en) 2008-12-16 2010-06-24 Labopharm Inc. Misuse preventative, controlled release formulation
BRPI0923836A2 (pt) 2008-12-31 2015-07-21 Upsher Smith Lab Inc Composições farmacêuticas orais contendo opióide e métodos
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
NZ603579A (en) 2009-06-24 2014-02-28 Egalet Ltd Controlled release formulations
EP2997965B1 (de) 2009-07-22 2019-01-02 Grünenthal GmbH Manipulationssichere darreichungsform für oxidationsempfindliche opioide
CA2765971C (en) 2009-07-22 2017-08-22 Gruenenthal Gmbh Hot-melt extruded controlled release dosage form
US20110052685A1 (en) * 2009-08-31 2011-03-03 Depomed, Inc. Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen
WO2011034554A1 (en) 2009-09-17 2011-03-24 Upsher-Smith Laboratories, Inc. A sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti -inflammatory drug
HUE035862T2 (en) 2009-09-28 2018-05-28 Intarcia Therapeutics Inc Rapid establishment and/or termination of substantial steady-state drug delivery
WO2011041414A1 (en) 2009-09-30 2011-04-07 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
CA2780294C (en) 2009-11-09 2018-01-16 Spotlight Technology Partners Llc Polysaccharide based hydrogels
EP2498764B1 (de) 2009-11-09 2017-09-06 Spotlight Technology Partners LLC Fragmentierte hydrogele
CN101711752B (zh) * 2009-11-26 2011-09-21 中国科学院上海药物研究所 一种苯并异噁唑类衍生物的控释制剂及其制备方法
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9579285B2 (en) 2010-02-03 2017-02-28 Gruenenthal Gmbh Preparation of a powdery pharmaceutical composition by means of an extruder
AU2011233663B2 (en) * 2010-04-03 2016-04-14 Praful Doshi Medical devices including medicaments and methods of making and using same
US8969327B2 (en) 2010-04-08 2015-03-03 Emory University Substituted androst-4-ene diones
WO2011143120A1 (en) 2010-05-11 2011-11-17 Cima Labs Inc. Alcoholres i stant metoprolol - containing extended - release oral dosage forms
US20130237559A1 (en) * 2010-06-30 2013-09-12 Ronnie Ortiz Sustained release composition comprising an amine as active agent and a salt of a cyclic organic acid
NZ606123A (en) * 2010-08-13 2015-03-27 Euro Celtique Sa Use of binders for manufacturing storage stable formulations
PE20131102A1 (es) 2010-09-02 2013-10-12 Gruenenthal Chemie Forma de dosificacion resistente a manipulacion que comprende una sal inorganica
AR082862A1 (es) 2010-09-02 2013-01-16 Gruenenthal Gmbh Forma de dosificacion resistente a alteracion que comprende un polimero anionico
CA2850468C (en) 2010-09-28 2019-08-13 Depomed, Inc. Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
CA2991217C (en) 2010-12-22 2020-06-09 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CA2830069C (en) 2011-03-20 2019-11-12 The University Of British Columbia Therapeutic agent for emphysema and copd
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US20140227293A1 (en) 2011-06-30 2014-08-14 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
US10702485B2 (en) 2011-07-09 2020-07-07 Syntrix Biosystems Inc. Compositions and methods for overcoming resistance to tramadol
AR087359A1 (es) 2011-07-29 2014-03-19 Gruenenthal Gmbh Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco
EA201400172A1 (ru) 2011-07-29 2014-06-30 Грюненталь Гмбх Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
EP2819656A1 (de) 2012-02-28 2015-01-07 Grünenthal GmbH Fälschungssichere dosierform mit einer pharmazeutisch aktiven verbindung und einem anionischen polymer
AU2013248351B2 (en) 2012-04-18 2018-04-26 Grunenthal Gmbh Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
NZ704011A (en) 2012-07-06 2016-04-29 Egalet Ltd Abuse deterrent pharmaceutical compositions for controlled release
JP6031599B2 (ja) 2012-07-12 2016-11-24 マリンクロッド エルエルシー 長期放出性、濫用抑止特性薬学的組成物
EP2925304B1 (de) 2012-11-30 2018-09-05 Acura Pharmaceuticals, Inc. Selbstregulierende freisetzung eines pharmazeutischen wirkstoffs
EP2953618B1 (de) 2013-02-05 2020-11-11 Purdue Pharma L.P. Manipulationssichere pharmazeutische formulierungen
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
DE102013009114A1 (de) 2013-05-29 2014-12-04 Franz Gerstheimer Pharmazeutische Zusammensetzung zur Überwindung von Metabolisierungsproblemen
AR096438A1 (es) 2013-05-29 2015-12-30 Gruenenthal Gmbh Forma de dosificación resistente al uso indebido con perfil de liberación bimodal, proceso
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
KR20160031526A (ko) 2013-07-12 2016-03-22 그뤼넨탈 게엠베하 에틸렌-비닐 아세테이트 중합체를 함유하는 템퍼 내성 투여형
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
WO2015027146A1 (en) 2013-08-22 2015-02-26 The General Hospital Corporation Inhibitors of human 12/15-lipoxygenase
BR112016010482B1 (pt) 2013-11-26 2022-11-16 Grünenthal GmbH Preparação de uma composição farmacêutica em pó por meio de criomoagem
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
HUE057649T2 (hu) 2013-12-24 2022-05-28 Us Gov Veterans Affairs Oxigenált koleszterinszulfátok (OCS) alkalmazása az akut májelégtelenség kezelésére
AU2015261060A1 (en) 2014-05-12 2016-11-03 Grunenthal Gmbh Tamper resistant immediate release capsule formulation comprising Tapentadol
MX2016015417A (es) 2014-05-26 2017-02-22 Gruenenthal Gmbh Multiparticulas protegidas contra vertido de dosis etanolico.
US10076504B2 (en) 2014-06-12 2018-09-18 Ligand Pharmaceuticals, Inc. Glucagon antagonists
ES2809458T3 (es) 2014-07-17 2021-03-04 Pharmaceutical Manufacturing Res Services Inc Forma de dosificación llena de líquido, disuasoria del abuso y de liberación inmediata
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CA2964628A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
GB201419454D0 (en) * 2014-10-31 2014-12-17 Cambrex Charles City Inc New process
JP2018503693A (ja) 2015-02-03 2018-02-08 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング ポリエチレングリコールグラフトコポリマーを含む改変防止剤形
WO2016170097A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
MX2017015137A (es) * 2015-05-25 2018-03-28 Sun Pharmaceutical Ind Ltd Composicion farmaceutica oral de dosis diaria de isotretinoin.
MX2017015504A (es) 2015-06-03 2018-05-15 Intarcia Therapeutics Inc Sistemas de colocacion y remoción de implante.
WO2017040607A1 (en) 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
JP2018526414A (ja) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
CA3024479A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
US10716761B2 (en) 2017-07-24 2020-07-21 Alcresta Therapeutics, Inc. Ingestible medical delivery devices
AU2018390826B2 (en) 2017-12-20 2024-09-12 Purdue Pharma L.P. Abuse deterrent morphine sulfate dosage forms
WO2019160940A1 (en) 2018-02-13 2019-08-22 Ligand Pharmaceuticals Incorporated Glucagon receptor antagonists
USD933219S1 (en) 2018-07-13 2021-10-12 Intarcia Therapeutics, Inc. Implant removal tool and assembly
US11000488B2 (en) 2019-03-22 2021-05-11 Syntrix Biosystems Inc. Treating pain using desmetramadol
US11294401B2 (en) 2020-07-08 2022-04-05 Saudi Arabian Oil Company Flow management systems and related methods for oil and gas applications
US11802645B2 (en) 2020-07-08 2023-10-31 Saudi Arabian Oil Company Flow management systems and related methods for oil and gas applications
US11314266B2 (en) 2020-07-08 2022-04-26 Saudi Arabian Oil Company Flow management systems and related methods for oil and gas applications
US11274501B2 (en) 2020-07-08 2022-03-15 Saudi Arabian Oil Company Flow management systems and related methods for oil and gas applications
US11256273B2 (en) 2020-07-08 2022-02-22 Saudi Arabian Oil Company Flow management systems and related methods for oil and gas applications
US11131158B1 (en) 2020-07-08 2021-09-28 Saudi Arabian Oil Company Flow management systems and related methods for oil and gas applications

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3173876A (en) 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (de) 1960-11-29
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
NL6714885A (de) 1967-11-02 1969-05-06
US3541005A (en) 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4014334A (en) 1976-02-02 1977-03-29 Alza Corporation Laminated osmotic system for dispensing beneficial agent
US4058122A (en) 1976-02-02 1977-11-15 Alza Corporation Osmotic system with laminated wall formed of different materials
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
EP0068838B1 (de) * 1981-06-26 1986-09-17 The Upjohn Company Analgetischer Prozess und Zusammensetzung
US4449983A (en) * 1982-03-22 1984-05-22 Alza Corporation Simultaneous delivery of two drugs from unit delivery device
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
WO1985003436A1 (en) * 1984-02-10 1985-08-15 A/S Alfred Benzon Diffusion coated multiple-units dosage form
JPS6129720U (ja) * 1984-07-28 1986-02-22 高砂医科工業株式会社 腸管吻合補助具
US4662880A (en) * 1986-03-14 1987-05-05 Alza Corporation Pseudoephedrine, brompheniramine therapy
US4863456A (en) 1986-04-30 1989-09-05 Alza Corporation Dosage form with improved delivery capability
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
JP3007387B2 (ja) * 1990-07-16 2000-02-07 エーザイ株式会社 徐放性製剤用基剤粉末
US5166145A (en) * 1990-09-10 1992-11-24 Alza Corporation Antiemetic therapy
US5160744A (en) 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5273760A (en) * 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
ATE195252T1 (de) * 1993-04-23 2000-08-15 Novartis Erfind Verwalt Gmbh Wirkstoffabgabevorrichtung mit gesteuerter freigabe
JPH0789849A (ja) * 1993-09-20 1995-04-04 Fujisawa Pharmaceut Co Ltd 徐放性製剤
GB9319568D0 (en) * 1993-09-22 1993-11-10 Euro Celtique Sa Pharmaceutical compositions and usages
EP1442745A1 (de) * 1993-10-07 2004-08-04 Euro-Celtique Oral anzuwendende opioidhaltige Zusammensetzungen mit verlängerter Wirkung
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US5914131A (en) * 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
US5529787A (en) * 1994-07-07 1996-06-25 Alza Corporation Hydromorphone therapy
US5621594A (en) * 1995-02-17 1997-04-15 Aiwa Research And Development, Inc. Electroplated thin film conductor coil assembly
US5840731A (en) * 1995-08-02 1998-11-24 Virginia Commonwealth University Pain-alleviating drug composition and method for alleviating pain
JPH0987203A (ja) * 1995-09-27 1997-03-31 Kanegafuchi Chem Ind Co Ltd 薬剤含有粒子及びその製造方法
JPH0995440A (ja) * 1995-09-29 1997-04-08 Roussel Morishita Kk 徐放性製剤およびその製造方法
JP3134187B2 (ja) * 1996-03-07 2001-02-13 武田薬品工業株式会社 放出制御組成物
FR2751875B1 (fr) * 1996-08-05 1998-12-24 Scr Newpharm Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation
DE69805001T2 (de) * 1997-12-05 2002-08-22 Alza Corp., Palo Alto Osmotische darreichungsform mit zwei mantelschichten
US5916595A (en) * 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor

Also Published As

Publication number Publication date
ES2248983T3 (es) 2006-03-16
AR015730A1 (es) 2001-05-16
JP2002505274A (ja) 2002-02-19
WO1999044591A1 (en) 1999-09-10
ES2357412T3 (es) 2011-04-26
ATE486589T1 (de) 2010-11-15
CY1111153T1 (el) 2015-06-11
EP1059916A1 (de) 2000-12-20
AU2791599A (en) 1999-09-20
EP1600154B1 (de) 2010-11-03
EP1384471A1 (de) 2004-01-28
DE69942921D1 (de) 2010-12-16
HK1033649A1 (en) 2001-09-14
DE69928085D1 (de) 2005-12-08
US6245357B1 (en) 2001-06-12
PT1600154E (pt) 2011-02-22
EP1600154A1 (de) 2005-11-30
DE69928085T2 (de) 2006-04-20
JP5143324B2 (ja) 2013-02-13
EP1059916B1 (de) 2005-11-02
DK1600154T3 (da) 2011-02-21

Similar Documents

Publication Publication Date Title
ATE308319T1 (de) Dosierungsform mit verlängerter wirkstoffabgabe
DE60038698D1 (de) Hydrogel-gesteuerte dosierungsform
DE50011454D1 (de) Handgeschirrspülmittel mit mikrokapseln
DE69834019D1 (de) Dose
ATE252386T1 (de) Galantamin-zusammensetzung mit gesteuerter freisetzung
DE60044873D1 (de) Orientierte biopolymermembrane
ID25977A (id) Popok sekali pakai
ID24555A (id) Popok sekali pakai
ID23076A (id) Popok sekali pakai
NO992692L (no) Nefadozon doseringsform
NO20003640D0 (no) Ny doseringsform
NO20004773D0 (no) Forlenget-frigjøringsblandinger
DE69928777D1 (de) Dosierspender
DE60043447D1 (de) Zusammensetzungen mit kontrollierter freigabe enthaltend nimesulid
DE69928582D1 (de) Förderer mit mehreren Trennmitteln
ID27776A (id) Bahan dengan efek antidepresan
FI990170A0 (fi) Maksunosoitus
ID30114A (id) Zat-zat herbisida dengan fenoksisulfonilurea tersubstitusi
DE50000494D1 (de) Funktionsträgeranordnung
DK1086701T3 (da) Simethiconholdigt laksans
EE200200150A (et) Preparaat
ID23083A (id) Popok sekali pakai
DE60143148D1 (de) En mit honigwaben
DE59904727D1 (de) Verpackung mit Aufreissverschluss
DE50015441D1 (de) Fadenliefergerät mit verstellbarer fadenleiteinrichtung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties